These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18282373)

  • 1. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
    Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
    Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.
    Pashko S; Johnson DH
    Pharmacoeconomics; 1992 Apr; 1(4):293-7. PubMed ID: 10147019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
    Doyle JJ; Dezii CM; Sadana A
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ["State-of-the-art" chemotherapy for small-cell lung cancer].
    Negoro S
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():398-404. PubMed ID: 9369914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
    Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
    Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.
    Zhou K; Wen F; Zhang P; Zhou J; Zheng H; Sun L; Li Q
    Clin Transl Oncol; 2018 Jun; 20(6):768-774. PubMed ID: 29098555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current standards of care in small-cell and non-small-cell lung cancer.
    Schiller JH
    Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer.
    Khan ZM; Rascati KL; Koeller JM
    Pharmacoeconomics; 1999 Jul; 16(1):43-57. PubMed ID: 10539121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
    Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.